Phaseline

Companies › ImmunoVaccine Technologies, Inc. (IMV Inc.)

ImmunoVaccine Technologies, Inc. (IMV Inc.): clinical trials, targets and expected readouts

1 active drug program in 4 registered trials: 3 Phase 2, 1 Phase 1; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
DPX-Survivac
Survivin-targeted immunogenic peptide vaccine
BIRC5Phase 2Ovarian Cancer; Relapsed Diffuse Large B-cell Lymphoma; Advanced Cancer; Breast Cancer–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04895761DPX-SurvivacPhase 1Breast CancerOncologyJun 2023
NCT03836352DPX-SurvivacPhase 2Ovarian CancerOncologyDec 2023
NCT04920617DPX-SurvivacPhase 2Relapsed Diffuse Large B-cell LymphomaOncologyOct 2024
NCT03029403DPX-SurvivacPhase 2Advanced CancerOncologyDec 2025

Targets

BIRC5 (1)

Companies with the same targets

–

Companies built like this

Vasgene Therapeutics Suzhou BlueHorse Therapeutics Pieris Pharmaceuticals Evaxion Biotech Primmune Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.